前列腺癌骨转移机制和骨靶向药物研究进展

doi:10.11904/j.issn.1002-3070.2023.03.009

Abstract

Abstract: Bone is the most common metastatic site of advanced prostate cancer(PCa).Various cytokines such as receptor activator of nuclear factor-κB ligand(RANKL),chemokine families,integrins,etc.in the bone microenvironment and PCa,are involved in bone metastasis of PCa through complex interaction mechanisms.Multiple bone-targeted drugs such as disphosphonate,denosumab,and radiotherapy drugs such as radium-223 have been approved for prevention and treatment of skeletal related events(SREs)caused by PCa bone metastases.This article reviews the biological mechanisms of prostate cancer bone metastasis and the research progression of bone-targeted drugs.

Key words: Prostate cancer, Mechanism of bone metastatic, Bone-targeted drugs

CLC Number:

R737.25

HAN Yansong, REN Minghua. Research progression in the mechanism of bone metastasis and bone-targeted drugs in prostate cancer[J]. Journal of Practical Oncology, 2023, 37(3): 252-256.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2023.03.009

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2023/V37/I3/252

References

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Nuhn P,De Bono JS,Fizazi K,et al.Update on systemic prostate cancer therapies:management of metastatic castration-resistant prostate cancer in the era of precision oncology[J].Eur Urol,2019,75(1):88-99.
3 Thalmann GN,Karkampouna S.Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer[J].Cancer Lett,2022,530:156-169.
4 Singh DK,Patel VG,Oh WK,et al.Prostate cancer dormancy and reactivation in bone marrow[J].J Clin Med,2021,10(12):2648.
5 Gartrell BA,Coleman R,Efstathiou E,et al.Metastatic prostate cancer and the bone:significance and therapeutic options[J].Eur Urol,2015,68(5):850-858.
6 Deng X,He G,Liu J,et al.Recent advances in bone-targeted therapies of metastatic prostate cancer[J].Cancer Treat Rev,2014,40(6):730-738.
7 Baci D,Bruno A,Cascini C,et al.Acetyl-L-Carnitine downregulates invasion(CXCR4/CXCL12,MMP-9)and angiogenesis(VEGF,CXCL8)pathways in prostate cancer cells:rationale for prevention and interception strategies[J].J Exp Clin Cancer Res,2019,38(1):464.
8 Midavaine E,Cote J,Sarret P.The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers[J].Cancer Metastasis Rev,2021,40(2):427-445.
9 Cioni B,Nevedomskaya E,Melis MHM,et al.Loss of androgen receptor signaling in prostate cancer-associated fibroblasts(CAFs)promotes CCL2-and CXCL8-mediated cancer cell migration[J].Mol Oncol,2018,12(8):1308-1323.
10 Siddiqui JA,Seshacharyulu P,Muniyan S,et al.GDF15 promotes prostate cancer bone metastasis and colonization through osteoblastic CCL2 and RANKL activation[J].Bone Res,2022,10(1):6.
11 Li Y,He Y,Butler W,et al.Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer[J].Sci Transl Med,2019,11(521):11-44.
12 Singh R,Kapur N,Mir H,et al.CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and αvβ3 integrin clustering[J].Oncotarget,2016,7(6):7343-7353.
13 Connell B,Kopach P,Ren W,et al.Aberrant integrin αv and α5 expression in prostate adenocarcinomas and bone-metastases is consistent with a bone-colonizing phenotype[J].Transl Androl Urol,2020,9(4):1630-1638.
14 Quayle L,Ottewell PD,Holen I.Bone metastasis:molecular mechanisms implicated in tumour cell dormancy in breast and prostate cancer[J].Curr Cancer Drug Targets,2015,15(6):469-480.
15 Yumoto K,Eber MR,Wang J,et al.Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow[J].Sci Rep,2016,6:36520.
16 Kobayashi A,Okuda H,Xing F,et al.Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone[J].J Exp Med,2011,208(13):2641-2655.
17 Park M,Cho YJ,Kim B,et al.RANKL immunisation inhibits prostate cancer metastasis by modulating EMT through a RANKL-dependent pathway[J].Sci Rep,2021,11(1):12186.
18 Ren D,Dai Y,Yang Q,et al.Wnt5a induces and maintains prostate cancer cells dormancy in bone[J].J Exp Med,2019,216(2):428-449.
19 Zhang X.Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer[J].Cancer Commun(Lond),2019,39(1):76.
20 Liu Q,Li A,Tian Y,et al.The CXCL8-CXCR1/2 pathways in cancer[J].Cytokine Growth Factor Rev,2016,31:61-71.
21 Danilucci TM,Santos PK,Pachane BC,et al.Recombinant RGD-disintegrin DisBa-01 blocks integrin αvβ3 and impairs VEGF signaling in endothelial cells[J].Cell Commun Signal,2019,17(1):27.
22 Decker AM,Jung Y,Cackowski FC,et al.Sympathetic signaling reactivates quiescent disseminated prostate cancer cells in the bone marrow[J].Mol Cancer Res,2017,15(12):1644-1655.
23 Wu AC,He Y,Broomfield A,et al.CD169(+)macrophages mediate pathological formation of woven bone in skeletal lesions of prostate cancer[J].J Pathol,2016,239(2):218-230.
24 Lin SC,Lee YC,Yu G,et al.Endothelial-to-osteoblast conversion generates osteoblastic metastasis of prostate cancer[J].Dev Cell,2017,41(5):467-480.
25 Zhang Y,Liang J,Liu P,et al.The RANK/RANKL/OPG system and tumor bone metastasis:potential mechanisms and therapeutic strategies[J].Front Endocrinol(Lausanne),2022,13:1063815.
26 Zhang B,Li Y,Wu Q,et al.Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer[J].Nat Commun,2021,12(1):1714.
27 Sun CY,Mi YY,Ge SY,et al.Tumor-and osteoblast-derived periostin in prostate cancer bone metastases[J].Front Oncol,2022,11:795712.
28 Saad F,Gleason D,Murray R,et al.A randomized,placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma[J].Natl Cancer Inst,2002,94:1458-1468.
29 Finianos A,Aragon-Ching JB.Zoledronic acid for the treatment of prostate cancer[J].Expert Opin Pharmacother,2019,20(6):657-666.
30 Landgraf M,Lahr CA,Sanchez-Herrero A,et al.Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of zoledronic acid in vivo[J].Bone Res,2019,7:31.
31 Hegemann M,Bedke J,Stenzl A,et al.Denosumab treatment in the management of patients with advanced prostate cancer:clinical evidence and experience[J].Ther Adv Urol,2017,9(3-4):81-88.
32 Zhang N,Zhang ZK,Yu Y,et al.Pros and cons of denosumab treatment for osteoporosis and implication for RANKL aptamer therapy[J].Front Cell Dev Biol,2020,8:325.
33 Jakob T,Tesfamariam YM,Macherey S,et al.Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases:a network meta-analysis[J].Cochrane Database Syst Rev,2020,12(12):CD013020.
34 Fizazi K,Carducci M,Smith M,et al.Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer:a randomised,double-blind study[J].Lancet,2011,377(9768):813-822.
35 van der Zande K,Oyen WJG,Zwart W,et al.Radium-223 treatment of patients with metastatic castration resistant prostate cancer:biomarkers for stratification and response evaluation[J].Cancers(Basel),2021,13(17):4346.
36 Parker C,Nilsson S,Heinrich D,et al.Alpha emitter radium-223 and survival in metastatic prostate cancer[J].N Engl J Med,2013,369(3):213-223.
37 Gomez Rivas J,Carrion DM,Alvarez-Maestro M,et al.Bone-targeted therapy in castration-resistant prostate cancer:where do we stand?[J].Minerva Urol Nefrol,2019,71(5):445-456.
38 Hu Z,Tian Y,Li W,et al.The efficacy and safety of zoledronic acid and strontium-89 in treating non-small cell lung cancer:a systematic review and meta-analysis of randomized controlled trials[J].Support Care Cancer,2020,(7):3291-3301.
39 Baba K,Kaida H,Hattori C,et al.Tumoricidal effect and pain relief after concurrent therapy by strontium-89 chloride and zoledronic acid for bone metastases[J].Hell J Nucl Med,2018,21(1):15-23.
40 Murray I,Du Y.Systemic radiotherapy of bone metastases with radionuclides[J].Clin Oncol(R Coll Radiol),2021,33(2):98-105.
41 Fioramonti M,Santini D,Iuliani M,et al.Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions[J].Oncotarget,2017,8(12):20113-20121.
42 Schoffski P,Gordon M,Smith DC,et al.Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours[J].Eur J Cancer,2017,86:296-304.
43 Smith DC,Daignault-Newton S,Grivas P,et al.Efficacy and effect of cabozantinib on bone metastases in treatment-naive castration-resistant prostate cancer[J].Clin Genitourin Cancer,2020,18(4):332-339.
44 Paindelli C,Casarin S,Wang F,et al.Enhancing 223Ra treatment efficacy by anti-β1 integrin targeting[J].J Nucl Med,2022,63(7):1039-1045.
45 Hill EE,Kim JK,Jung Y,et al.Integrin alphaV beta3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis[J].J Cell Biochem,2018,119(10):8074-8083.

[1]	ZHOU Mengmeng, XU Wenchao, YU Hao. Analysis of disease burden of prostate cancer among men in Jiangsu province from 1990 to 2019 [J]. Journal of Practical Oncology, 2023, 37(1): 1-5.
[2]	LI Hao, TENG Lichen. Research status of exosomal circular RNA in prostate cancer [J]. Journal of Practical Oncology, 2023, 37(1): 92-96.
[3]	GAO Ke, REN Minghua. Current status of drug therapy for castration-resistant prostate cancer [J]. Journal of Practical Oncology, 2021, 35(4): 376-379.
[4]	MIAO Pengcheng, KANG Yindong, LI Fudong, MENG Dongdong, WANG Dongxing, CHANG Dehui. Research progress of lncRNA SNHGs in the occurrence and development of prostate cancer [J]. Journal of Practical Oncology, 2020, 34(5): 446-450.
[5]	JIANG Tao,ZHANG Xu. The research progress of orphan nuclear receptors in prostate cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 377-380.
[6]	LI Jiebing,ZHANG Yanhua,YANG Hongyan,ZHANG Cui,LI Bo,CHENG Wen. Development of prostate cancer risk in patients with chronic prostate inflammation and wHGPIN during puncture rebiopsy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(3): 217-221.
[7]	MAO Gaocai,ZHU Qicong,SHEN Hongfeng,TU Ruisha,YAN Qingguo. The clinicopathology analysis of three cases of carcinoma with multi-directional differentiation derived from junction of bladder and prostate [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 538-542.

Research progression in the mechanism of bone metastasis and bone-targeted drugs in prostate cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 7

Recommended Articles

Metrics

Comments